Jyong Biotech (MENS) vs Satellos Bioscience (MSLE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Satellos Bioscience (MSLE) has outperformed Jyong Biotech (MENS) over the past year, gaining 7.4% versus a loss of 95.9%. Jyong Biotech is the larger company by market cap ($159.7 million vs $155.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MENS | MSLE |
|---|---|---|
| Share price | $2.10 | $7.35 |
| Market cap | $159.66M | $155.83M |
| 1-day change | +2.44% | -3.74% |
| YTD return | -46.84% | +24.91% |
| 1-year return | -95.89% | +7.38% |
| 5-year return | — | -50.84% |
| EPS (TTM) | $-0.06 | $-1.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $63.00 | $13.40 |
| 52-week low | $1.43 | $5.30 |
| Distance from 52-week high | -96.67% | -45.17% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +251.26% |
| Average volume | 45.62K | 50.10K |
| Shares outstanding | 74.23M | 21.22M |
| Employees | 27 | 18 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MSLE has outperformed MENS by 103.3 percentage points over the past year.
- The two companies sit in different sectors: Jyong Biotech in Health Care and Satellos Bioscience in Healthcare.
About Jyong Biotech
MENS stock →Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
About Satellos Bioscience
MSLE stock →Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo.
Healthcare · Biotechnology · 18 employees
MENS vs MSLE FAQ
Which is bigger, Jyong Biotech or Satellos Bioscience?
Jyong Biotech (MENS) is larger, with a market capitalization of $159.66M compared with $155.83M for Satellos Bioscience (MSLE).
Which stock has performed better over the past year, MENS or MSLE?
MSLE returned +7.38% over the past 12 months, compared with -95.89% for MENS (price return, excluding dividends). Past performance does not predict future results.
Are Jyong Biotech and Satellos Bioscience in the same industry?
No. Jyong Biotech is in the Health Care sector, while Satellos Bioscience is in Healthcare.